These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 18056450)

  • 41. Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformations.
    You C; Sandalcioglu IE; Dammann P; Felbor U; Sure U; Zhu Y
    J Cell Mol Med; 2013 Mar; 17(3):407-18. PubMed ID: 23388056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor.
    Middeke M; Hoffmann S; Hassan I; Wunderlich A; Hofbauer LC; Zielke A
    Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):386-92. PubMed ID: 12518248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.
    Zielke A; Middeke M; Hoffmann S; Colombo-Benkmann M; Barth P; Hassan I; Wunderlich A; Hofbauer LC; Duh QY
    Surgery; 2002 Dec; 132(6):1056-63; discussion 1063. PubMed ID: 12490855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation.
    Yin YJ; Salah Z; Maoz M; Even Ram SC; Ochayon S; Neufeld G; Katzav S; Bar-Shavit R
    FASEB J; 2003 Feb; 17(2):163-74. PubMed ID: 12554695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice.
    Reynolds AR; Reynolds LE; Nagel TE; Lively JC; Robinson SD; Hicklin DJ; Bodary SC; Hodivala-Dilke KM
    Cancer Res; 2004 Dec; 64(23):8643-50. PubMed ID: 15574772
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic impact of δ-like ligand 4 and Notch1 in acute myeloid leukemia.
    Zhang J; Ma D; Ye J; Zang S; Lu F; Yang M; Qu X; Sun X; Ji C
    Oncol Rep; 2012 Oct; 28(4):1503-11. PubMed ID: 22858860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
    Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
    Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors.
    Indraccolo S
    Adv Exp Med Biol; 2013; 734():37-52. PubMed ID: 23143974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.
    Yen WC; Fischer MM; Hynes M; Wu J; Kim E; Beviglia L; Yeung VP; Song X; Kapoun AM; Lewicki J; Gurney A; Simeone DM; Hoey T
    Clin Cancer Res; 2012 Oct; 18(19):5374-86. PubMed ID: 22952347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
    Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
    MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
    Zhu Z; Hattori K; Zhang H; Jimenez X; Ludwig DL; Dias S; Kussie P; Koo H; Kim HJ; Lu D; Liu M; Tejada R; Friedrich M; Bohlen P; Witte L; Rafii S
    Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vascular endothelial growth factor as a marker of tumor endothelium.
    Brekken RA; Huang X; King SW; Thorpe PE
    Cancer Res; 1998 May; 58(9):1952-9. PubMed ID: 9581838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
    Fahmy RG; Dass CR; Sun LQ; Chesterman CN; Khachigian LM
    Nat Med; 2003 Aug; 9(8):1026-32. PubMed ID: 12872165
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delta-like ligand 4-notch blockade and tumor radiation response.
    Liu SK; Bham SA; Fokas E; Beech J; Im J; Cho S; Harris AL; Muschel RJ
    J Natl Cancer Inst; 2011 Dec; 103(23):1778-98. PubMed ID: 22010178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.